TheraVida theravida.com


Public lists: Pharma Startups (4732)

TheraVida is developing a combination drug product platform, with the potenial to significantly improve existing therapies for a variety of diseases. The company is currently focusing its efforts on the treatment of urological disorders.

TheraVida is developing a combination drug product platform, with the potenial to significantly improve existing therapies for a variety of diseases. The company is currently focusing its efforts on the treatment of urological disorders.

Company (Alive / Active)

Phone: 650-401-2000

Fax: 650-903-2225

800 W. El Camino Real
Suite 180
Mountain View, 94040
California, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
TheraVida $5.1M Jul 14, 2010
See all 18 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related TheraVida Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 1 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

NeuroGenomeX

Madison, Wisconsin, United States
Alive / ActiveNeuroGenomeX is a drug discovery company developing novel treatments for diseases of the brain and nervous system. The current NeuroGenomeX discovery program is focused on therapeutic target areas of epilepsy and traumatic brain injury. NeuroGenomeX is advancing its lead drug candidate, 2-deoxy-D-glucose (2DG), as an anticonvulsant that stops seizures and has beneficial effects against adverse long-term consequences of epilepsy. 2DG also has shown favorable therapeutic neuroprotective effects in...Show allLogin to see details

Ceregene

San Diego, California, United States
AcquiredCeregene is a San Diego-based biotechnology company focused on the development of nervous system growth factors (neurotrophic factors) as treatments for neurodegenerative and retinal disorders using gene transfer for their delivery. The company has established a position in the fields of gene therapy and neurotrophic factors, having launched separate clinical trials in Parkinson's and Alzheimer's disease, enrolling a total of nearly 200 patients, over 100 whom have been administered the gene the...Show allLogin to see details
See all 18 competitors